ExpreS2ion Biotech Holding has announced that the fully owned subsidiary ExpreS2ion Biotechnologies has entered a collaboration with the Germany based Institut Virion\Serion GmbH.
Virion is granted access to evaluate a number of new in vitro diagnostic product candidates, as well as commercial rights to promote, sell and distribute protein antigens produced using ExpreS2.
The financial terms of the agreements are not disclosed, but ExpreS2ion expects to generate annual revenues in excess of 250,000 EUR as a result of these agreements, when the collaboration is implemented.
“We are very pleased to have entered this broad collaboration in the expanding field of in vitro diagnostics. The Institut Virion\Serion GmbH is an established, strong, and growing player in this market, and we look forward to support their development with our competences, and the strength of our ExpreS2 platform,” said Dr. Steen Klysner, CEO.